Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.
Department of Neuro-Oncology Research, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.
Mol Imaging Biol. 2021 Aug;23(4):586-596. doi: 10.1007/s11307-021-01579-z. Epub 2021 Feb 5.
This study evaluated the use of molecular imaging of fluorescent glucose analog 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) as a discriminatory marker for intraoperative tumor border identification in a murine glioma model.
2-NBDG was assessed in GL261 and U251 orthotopic tumor-bearing mice. Intraoperative fluorescence of topical and intravenous 2-NBDG in normal and tumor regions was assessed with an operating microscope, handheld confocal laser scanning endomicroscope (CLE), and benchtop confocal laser scanning microscope (LSM). Additionally, 2-NBDG fluorescence in tumors was compared with 5-aminolevulinic acid-induced protoporphyrin IX fluorescence.
Intravenously administered 2-NBDG was detectable in brain tumor and absent in contralateral normal brain parenchyma on wide-field operating microscope imaging. Intraoperative and benchtop CLE showed preferential 2-NBDG accumulation in the cytoplasm of glioma cells (mean [SD] tumor-to-background ratio of 2.76 [0.43]). Topically administered 2-NBDG did not create sufficient tumor-background contrast for wide-field operating microscope imaging or under benchtop LSM (mean [SD] tumor-to-background ratio 1.42 [0.72]). However, topical 2-NBDG did create sufficient contrast to evaluate cellular tissue architecture and differentiate tumor cells from normal brain parenchyma. Protoporphyrin IX imaging resulted in a more specific delineation of gross tumor margins than intravenous or topical 2-NBDG and a significantly higher tumor-to-normal-brain fluorescence intensity ratio.
After intravenous administration, 2-NBDG selectively accumulated in the experimental brain tumors and provided bright contrast under wide-field fluorescence imaging with a clinical-grade operating microscope. Topical 2-NBDG was able to create a sufficient contrast to differentiate tumor from normal brain cells on the basis of visualization of cellular architecture with CLE. 5-Aminolevulinic acid demonstrated superior specificity in outlining tumor margins and significantly higher tumor background contrast. Given the nontoxicity of 2-NBDG, its use as a topical molecular marker for noninvasive in vivo intraoperative microscopy is encouraging and warrants further clinical evaluation.
本研究评估了荧光葡萄糖类似物 2-(N-(7-硝基苯并-2-氧代-1,3-二唑-4-基)氨基)-2-脱氧葡萄糖(2-NBDG)的分子成像作为一种鉴别标志,用于在小鼠神经胶质瘤模型中识别术中肿瘤边界。
在 GL261 和 U251 原位肿瘤荷瘤小鼠中评估 2-NBDG。在手术显微镜、手持式共聚焦激光扫描内窥(endomicroscope)(CLE)和台式共聚焦激光扫描显微镜(LSM)下评估局部和静脉内 2-NBDG 在正常和肿瘤区域的术中荧光。此外,将肿瘤内的 2-NBDG 荧光与 5-氨基乙酰丙酸诱导的原卟啉 IX 荧光进行比较。
静脉内给予的 2-NBDG 在宽场手术显微镜成像中可检测到脑肿瘤,而在对侧正常脑实质中不可检测。术中及台式 CLE 显示 2-NBDG 优先在神经胶质瘤细胞的细胞质中积累(肿瘤与背景的平均[标准差]比值为 2.76[0.43])。局部给予的 2-NBDG 不足以在宽场手术显微镜成像或台式 LSM 下产生足够的肿瘤-背景对比度(肿瘤与背景的平均[标准差]比值为 1.42[0.72])。然而,局部 2-NBDG 确实足以评估细胞组织结构,并将肿瘤细胞与正常脑实质区分开来。原卟啉 IX 成像比静脉内或局部 2-NBDG 更能特异性地描绘大体肿瘤边界,并且肿瘤与正常脑荧光强度比值显著更高。
静脉内给予后,2-NBDG 选择性地在实验性脑肿瘤中积累,并在具有临床级别的手术显微镜下的宽场荧光成像中提供明亮的对比度。局部 2-NBDG 能够通过 CLE 观察细胞结构来产生足够的对比度,将肿瘤与正常脑细胞区分开来。5-氨基乙酰丙酸在描绘肿瘤边界方面具有更高的特异性,并且肿瘤与背景的对比度显著更高。鉴于 2-NBDG 的非毒性,其作为非侵入性术中体内显微镜检查的局部分子标志物的使用令人鼓舞,值得进一步的临床评估。